Brokerages Set Tetraphase Pharmaceuticals, Inc. (TTPH) PT at $14.00

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has been assigned a consensus recommendation of “Hold” from the nine analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $14.00.

TTPH has been the subject of several research reports. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 price objective for the company in a research report on Wednesday, August 9th. Stifel Nicolaus upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price objective for the company from $8.00 to $15.00 in a research report on Wednesday, July 26th. HC Wainwright initiated coverage on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They issued a “buy” rating and a $15.00 price objective for the company. Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Sunday, September 17th. Finally, BidaskClub upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd.

Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded down 0.935% during mid-day trading on Tuesday, reaching $6.885. 266,563 shares of the company were exchanged. The firm’s 50-day moving average is $6.94 and its 200-day moving average is $7.27. Tetraphase Pharmaceuticals has a 12 month low of $3.11 and a 12 month high of $9.93. The company’s market capitalization is $351.50 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.07). The company had revenue of $1.59 million during the quarter, compared to analyst estimates of $1.54 million. Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The company’s revenue was up 28.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.47) EPS. On average, equities analysts forecast that Tetraphase Pharmaceuticals will post ($2.85) earnings per share for the current fiscal year.

In other news, insider Jacques Dumas sold 17,500 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $6.00, for a total transaction of $105,000.00. Following the completion of the sale, the insider now owns 17,500 shares in the company, valued at approximately $105,000. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 5.50% of the company’s stock.

Large investors have recently modified their holdings of the company. AXA acquired a new stake in shares of Tetraphase Pharmaceuticals during the 2nd quarter worth approximately $132,000. Citadel Advisors LLC grew its position in shares of Tetraphase Pharmaceuticals by 18.6% during the 1st quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 2,496 shares during the period. Virtu KCG Holdings LLC acquired a new stake in shares of Tetraphase Pharmaceuticals during the 2nd quarter worth approximately $147,000. Voya Investment Management LLC grew its position in shares of Tetraphase Pharmaceuticals by 17.8% during the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 3,104 shares during the period. Finally, UBS Group AG grew its position in shares of Tetraphase Pharmaceuticals by 2.3% during the 1st quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 387 shares during the period. Institutional investors own 41.73% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.truebluetribune.com/2017/10/13/brokerages-set-tetraphase-pharmaceuticals-inc-ttph-pt-at-14-00.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply